Uso isolado e combinado de bisfosfonatos, estatina e flavonóide em ratas osteoporóticas

ABSTRACT. Amaral G.G., Del Carlo R.J., Oliveira T.T., Louzada M.J.Q., Valadares R.F.D., Ribeiro M.D. & Pinto A.S. [Isolated and combined use of bisphosphonates, statins and flavonoids in osteoporotic female rat.] Uso isolado e combinado de bisfosfonatos, estatina e flavonoide em ratas osteoporoticas. Revista Brasileira de Medicina Veterinaria, 36(1):105-110, 2014. Programa de Pos- -Graduacao em Ciencias Veterinarias, Departamento de Veterinaria, Universidade Federal de Vicosa, Av. Peter Henry Rolfs, S/N, Vicosa, MG 36571-000, Brasil. E-mail: aloisio@ufv.br This study aimed to treat osteoporosis induced by ovariectomy through the single and combined use, by employing, in this case, half of the defined doses of the isolated compounds etidronate, risedronate (bisphosphonates), pravastatin (statin) and ipriflavone (flavonoid).The experiment consisted of 66 rats were divided into 11 groups of 6 animals, taking control and osteoporosis, the most isolated groups etidronate, risedronate, pravastatin and ipriflavone and associated etidronate + pravastatin, etidronate + ipriflavone, risedronate + pravastatin, risedronate + ipriflavone and pravastatin + ipriflavone. After 12 weeks of ovariectomy, began administering the drug orally for 30 days. After 35 days, the animals were sacrificed and blood was collected for biochemical analysis and the tibias for analysis bone mineral density.The value of the biochemical markers calcium, phosphorus, albumin, total protein and bone alkaline phosphatase presented no statistically significant differences. These results provide no information for the diagnosis and monitoring of osteoporosis. Bone densitometry presented significant results for induction and for different treatments, in relation to the osteoporotic group. The results reveal that associations have the same pharmacological activity as isolated substances, and no antagonistic effect was observed. Thus, associations can be a therapeutic alternative, since possible side effects can be reduced by the administration of half the individual dose prescribed.

[1]  Priscila Lima Sequetto.  Efeitos de alendronato de sódio, sinvastatina, crisina e tintura de Camellia sinensis na osteoporose induzida por dexametasona em ratas , 2008 .

[2]  A. Dalkin,et al.  Combination therapy for treatment of osteoporosis: A review. , 2007, American journal of obstetrics and gynecology.

[3]  M. Kumegawa,et al.  Inhibitory effect of ipriflavone on osteoclast-mediated bone resorption and new osteoclast formation in long-term cultures of mouse unfractionated bone cells , 1993, Calcified Tissue International.

[4]  R. J. D. Carlo,et al.  Efeitos de alendronato de sódio, atorvastatina cálcica e ipriflavona sobre a osteoporose induzida com dexametasona em ratas , 2005 .

[5]  G. H. Bell,et al.  Variations in strength of vertebrae with age and their relation to osteoporosis , 2005, Calcified Tissue Research.

[6]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[7]  M. Rhee,et al.  Studies on the effects of biomedicinal agents on serum concentration of Ca2+, P and ALP activity in osteoporosis-induced rats. , 2003, Journal of veterinary science.

[8]  C. Jerome,et al.  Nonhuman primate models in skeletal research. , 2001, Bone.

[9]  R. Lindsay,et al.  Parathyroid Hormone Added to Established Hormone Therapy: Effects on Vertebral Fracture and Maintenance of Bone Mass After Parathyroid Hormone Withdrawal , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  A. Chines,et al.  Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. , 2001, The Journal of clinical endocrinology and metabolism.

[11]  E. Barengolts,et al.  The Synthetic Phytoestrogen, Ipriflavone, and Estrogen Prevent Bone Loss by Different Mechanisms , 2000, Calcified Tissue International.

[12]  J. Vieira.  Considerações sobre os marcadores bioquímicos do metabolismo ósseo e sua utilidade prática , 1999 .

[13]  P. Hess,et al.  Measurement of the , 1999 .

[14]  A. Turner,et al.  In search of an animal model for postmenopausal diseases. , 1998, Frontiers in bioscience : a journal and virtual library.

[15]  D. Bikle.  Biochemical markers in the assessment of bone disease. , 1997, The American journal of medicine.

[16]  D. Wilkie,et al.  Morphological and structural characteristics of the proximal femur in human and rat. , 1997, Bone.

[17]  H. Fleisch,et al.  Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. , 1996, Endocrinology.

[18]  X Marchandise,et al.  Methods for quantitative analysis of trabecular bone structure. , 1995, Revue du rhumatisme.

[19]  D. Thompson,et al.  FDA Guidelines and animal models for osteoporosis. , 1995, Bone.

[20]  R. Lindsay,et al.  Temporal changes in cancellous bone structure of rats immediately after ovariectomy. , 1995, Bone.

[21]  L. Solimeno,et al.  Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  I. Fogelman,et al.  Measurement of bone mass. , 1992, Bone.

[23]  L. Mosekilde,et al.  Biomechanical competence of vertebral trabecular bone in relation to ash density and age in normal individuals. , 1987, Bone.